Search results
Results from the WOW.Com Content Network
South Africa (1971), India (1984), United Nations (1971–1988) Withdrawn because of risk of addiction and overdose [33] [34] Metipranolol: 1990 UK, others Uveitis. [3] Metofoline: 1965 US Unspecific experimental toxicity. [3] Mibefradil: 1998 European Union, Malaysia, US, others Fatal arrhythmia, drug interactions. [2] [3] Minaprine: 1996 ...
Early 20th century "Frog In Your Throat" box, containing lozenges made of cubeb, tolu balsam, liquorice, white horehound and wild cherry extracts.. Candies to soothe the throat date back to 1000 BC in Egypt's Twentieth Dynasty, when they were made from honey flavored with citrus, herbs, and spices.
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
At this point, competitiveness becomes increasingly driven by higher education and training (pillar 5), efficient goods markets (pillar 6), efficient labor markets (pillar 7), developed financial markets (pillar 8), the ability to harness the benefits of existing technologies (pillar 9), and its market size, both domestic and international ...
The following list sorts countries by the total market capitalization of all domestic companies [clarification needed] listed in the country, according to data from the World Bank. Market capitalization, commonly called market cap, is the market value of a publicly traded company's outstanding shares. [1]
Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). [4] The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. [5 ...
In November 2010, Mylanta was voluntarily recalled [2] due to what is described as some labelling concerns. According to sources within the company at that time, these concerns stemmed from the fact that small traces of alcohol were found in the flavoring agents of the liquid version of the antacid which was not disclosed on the labelling itself, and that the problem would be rectified "shortly".
The indication was 10 to 20 mg (1.0mL from MDV's, up to one full single-use ampoule) to produce a focused, talkative state that could help certain patients break down the resistance to therapy. Parenteral methylphenidate was discontinued out of a concern for the actual benefit and of inducing a psychic dependence.